Limits...
Expression and clinical significance of YAP, TAZ, and AREG in hepatocellular carcinoma.

Han SX, Bai E, Jin GH, He CC, Guo XJ, Wang LJ, Li M, Ying X, Zhu Q - J Immunol Res (2014)

Bottom Line: The expression of YAP was significantly correlated with Edmondson stage (P>0.05), serum AFP level (P>0.05), and HCC prognosis (P>0.05).AREG expression was also significantly correlated with Edmondson stage (P>0.05) and serum AFP level (P>0.05).Further multivariate analysis showed that YAP expression was an independent prognostic factor that significantly affected the overall survival of HCC patients.

View Article: PubMed Central - PubMed

Affiliation: Department of Medical Oncology, The First Affiliated Hospital of Xi'an Jiaotong University Medical College, Xi'an, Shaanxi 710061, China.

ABSTRACT

Purpose: Yes-associated protein (YAP) and PDZ-binding motif (TAZ) are two important effectors of Hippo pathway controlling the balance of organ size and carcinogenesis. Amphiregulin (AREG) is a member of the epidermal growth factor family, a direct target gene of YAP and TAZ. The role of these proteins in hepatocellular carcinoma (HCC) is unclear.

Methods: The expression of YAP, TAZ, and AREG in HCC was analyzed by immunohistochemical staining. The level of secreted serum AREG was also assayed by enzyme-linked immunosorbent (ELISA) assay.

Results: YAP, TAZ, and AREG were expressed in 69.2% (27/39), 66.7% (26/39), and 61.5% (24/39) of HCC patients. The expression of YAP was significantly correlated with Edmondson stage (P>0.05), serum AFP level (P>0.05), and HCC prognosis (P>0.05). AREG expression was also significantly correlated with Edmondson stage (P>0.05) and serum AFP level (P>0.05). In addition, the expression of serum AREG was higher than serum AFP in HCC patients. Further multivariate analysis showed that YAP expression was an independent prognostic factor that significantly affected the overall survival of HCC patients.

Conclusions: YAP maybe an independent prognostic indicator for HCC patients and serum AREG may be a serological biomarker of HCC.

Show MeSH

Related in: MedlinePlus

(a) Twelve patients with HCC who underwent postoperative adjunctive therapy during two-year follow-up. At last all of them had tumor recurrence or metastasis, and some of them were dead. The sample of postoperation 1-2 weeks of patients number 3/210/277 was not collected; (b) levels of sera AREG from another six HCC patients were showed after operation and during follow-up.
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4016924&req=5

fig4: (a) Twelve patients with HCC who underwent postoperative adjunctive therapy during two-year follow-up. At last all of them had tumor recurrence or metastasis, and some of them were dead. The sample of postoperation 1-2 weeks of patients number 3/210/277 was not collected; (b) levels of sera AREG from another six HCC patients were showed after operation and during follow-up.

Mentions: Next, we examined AREG expression in HCC tissues (as shown in Figures 1(e) and 1(f)). 61.5% (24/39) of HCC tissues had high AREG expression and 56.0% (28/50) of HCC serum from patients had high serum AREG levels above the cut-off value of 14.993 pg/mL. In order to determine whether concentration of serum AREG would change with the development of clinical treatment, a follow-up study was performed over a two-year period. In the study, 47 of 50 HCC patients were observed over the course of two years (3 HCC patients lost to follow-up) and sera were collected from these 47 HCC patients in 1-2 weeks after tumor resection, postoperative chemotherapy, or hepatic arterial chemotherapy. During the follow-up of 47 HCC patients, 18 HCC patients underwent operation or transcatheter arterial chemoembolization (TACE) treatment. Of these 18 HCC patients, serum AREG levels were elevated in 12 HCC patients before operation and decreased in 5 HCC patients (5/12, 41.7%) after operation, while being slightly elevated in 2 HCC patients and significantly elevated in 9 patients after TACE. At last, 12 HCC patients were observed with tumor recurrence and metastasis (as shown in Figure 4(a)) (We are not able to get the detailed clinical information. This is a limitation of this study.) In another six HCC patients, serum AREG level decreased after operation and TACE (as shown in Figure 4(b)). They had better prognosis compare to above 12 HCC patients. Of 47 HCC patients, 20 HCC patients were deceased in the end of follow-up.


Expression and clinical significance of YAP, TAZ, and AREG in hepatocellular carcinoma.

Han SX, Bai E, Jin GH, He CC, Guo XJ, Wang LJ, Li M, Ying X, Zhu Q - J Immunol Res (2014)

(a) Twelve patients with HCC who underwent postoperative adjunctive therapy during two-year follow-up. At last all of them had tumor recurrence or metastasis, and some of them were dead. The sample of postoperation 1-2 weeks of patients number 3/210/277 was not collected; (b) levels of sera AREG from another six HCC patients were showed after operation and during follow-up.
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4016924&req=5

fig4: (a) Twelve patients with HCC who underwent postoperative adjunctive therapy during two-year follow-up. At last all of them had tumor recurrence or metastasis, and some of them were dead. The sample of postoperation 1-2 weeks of patients number 3/210/277 was not collected; (b) levels of sera AREG from another six HCC patients were showed after operation and during follow-up.
Mentions: Next, we examined AREG expression in HCC tissues (as shown in Figures 1(e) and 1(f)). 61.5% (24/39) of HCC tissues had high AREG expression and 56.0% (28/50) of HCC serum from patients had high serum AREG levels above the cut-off value of 14.993 pg/mL. In order to determine whether concentration of serum AREG would change with the development of clinical treatment, a follow-up study was performed over a two-year period. In the study, 47 of 50 HCC patients were observed over the course of two years (3 HCC patients lost to follow-up) and sera were collected from these 47 HCC patients in 1-2 weeks after tumor resection, postoperative chemotherapy, or hepatic arterial chemotherapy. During the follow-up of 47 HCC patients, 18 HCC patients underwent operation or transcatheter arterial chemoembolization (TACE) treatment. Of these 18 HCC patients, serum AREG levels were elevated in 12 HCC patients before operation and decreased in 5 HCC patients (5/12, 41.7%) after operation, while being slightly elevated in 2 HCC patients and significantly elevated in 9 patients after TACE. At last, 12 HCC patients were observed with tumor recurrence and metastasis (as shown in Figure 4(a)) (We are not able to get the detailed clinical information. This is a limitation of this study.) In another six HCC patients, serum AREG level decreased after operation and TACE (as shown in Figure 4(b)). They had better prognosis compare to above 12 HCC patients. Of 47 HCC patients, 20 HCC patients were deceased in the end of follow-up.

Bottom Line: The expression of YAP was significantly correlated with Edmondson stage (P>0.05), serum AFP level (P>0.05), and HCC prognosis (P>0.05).AREG expression was also significantly correlated with Edmondson stage (P>0.05) and serum AFP level (P>0.05).Further multivariate analysis showed that YAP expression was an independent prognostic factor that significantly affected the overall survival of HCC patients.

View Article: PubMed Central - PubMed

Affiliation: Department of Medical Oncology, The First Affiliated Hospital of Xi'an Jiaotong University Medical College, Xi'an, Shaanxi 710061, China.

ABSTRACT

Purpose: Yes-associated protein (YAP) and PDZ-binding motif (TAZ) are two important effectors of Hippo pathway controlling the balance of organ size and carcinogenesis. Amphiregulin (AREG) is a member of the epidermal growth factor family, a direct target gene of YAP and TAZ. The role of these proteins in hepatocellular carcinoma (HCC) is unclear.

Methods: The expression of YAP, TAZ, and AREG in HCC was analyzed by immunohistochemical staining. The level of secreted serum AREG was also assayed by enzyme-linked immunosorbent (ELISA) assay.

Results: YAP, TAZ, and AREG were expressed in 69.2% (27/39), 66.7% (26/39), and 61.5% (24/39) of HCC patients. The expression of YAP was significantly correlated with Edmondson stage (P>0.05), serum AFP level (P>0.05), and HCC prognosis (P>0.05). AREG expression was also significantly correlated with Edmondson stage (P>0.05) and serum AFP level (P>0.05). In addition, the expression of serum AREG was higher than serum AFP in HCC patients. Further multivariate analysis showed that YAP expression was an independent prognostic factor that significantly affected the overall survival of HCC patients.

Conclusions: YAP maybe an independent prognostic indicator for HCC patients and serum AREG may be a serological biomarker of HCC.

Show MeSH
Related in: MedlinePlus